New endocrine therapy for patients with scirrhous type gastric cancer using LH-RH analogue (Zoladex)

使用 LH-RH 类似物 (Zoladex) 治疗硬质型胃癌患者的新内分泌疗法

• 批准号: 05671079
• 负责人: KOJIMA Osamu
• 金额: $ 1.34万
• 依托单位: Kyoto Prefectural University of Medicine
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for General Scientific Research (C)
• 财政年份: 1993
• 资助国家: 日本
• 起止时间: 1993 至 1994
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-05671079/
• 关键词: Scirrhous-type gastric cancer; Zoladex; LH-RH analogue; Endocrine-therapy; Estrogen receptor; Estrogen; KATO-III; エストロジエン; ゴナドトロピン

In order to improving prognosis of scirrhous type gastric cancer patients, we studied new endocrine therapy using LH-RH analogue (Zoladex). 1. Studies on inhibition of cancer cell line. It was found that the proliferation of the KATO-III cell line (estrogenreceptor-positivecell) was inhibited by 1x10^<-6>-10^<-7>M Zoladex with E_2. On the other hand, the proliferation of MKOI (ER negative cell) was not inhibited by 1x10^<-6>-10^<-7>M Zoladex with E_2. In nude mouse bearing xenograft tumor, Kato-III cells were inhibited by Zoladex. In patients with scirrhous-type gastric cancer, the levels of serum estrogen decreased after administration of Zoladex. However, it was not clear that the size of scirrhous-type gastric cancer decreased by Zoladex. In the present study, it can be concluded that Zoladex might be useful for the treatment of scirrhous-type gastric cacer.

为了改善Scirhous型胃癌患者的预后，我们使用LH-RH类似物（Zoladex）研究了新的内分泌治疗。 1。抑制癌细胞系的研究。发现Kato-III细胞系（雌激素受体 - 杆菌）的增殖被1x10^<-6> -6> -10^<-7> M Zoladex用E_2抑制。另一方面，用E_2的1x10^<-6> -10^<-7> m Zoladex抑制MKOI（ER负细胞）的增殖。在带有异种移植肿瘤的裸小鼠中，Zoladex抑制了Kato-III细胞。在患有Scirrhous型胃癌的患者中，给药后血清雌激素的水平降低。但是，尚不清楚Zoladex的Scirhous型胃癌的大小降低。在本研究中，可以得出结论，Zoladex可能对治疗Scirrhous型胃cacer有用。

项目成果

小島 治: "胃癌組織内におけるc-erbB_2と蛋白とeotrogen receptor の局在と予後に関する研究" 京府医大誌. 102. 1429-1434 (1993)

小岛修：“胃癌组织中 c-erbB_2、蛋白质和 eotrogen 受体的定位和预后研究”京都府立医科大学学报 102. 1429-1434 (1993)

O.Kojima: "Study on relationship between prognosis of patients with gastric cancer and localization of c-erbB_2 protein and estrogen receptor." J.Kyoto Prefect.Univ.Med.102. 1429-1434 (1993)

O.Kojima：“胃癌患者预后与c-erbB_2蛋白和雌激素受体定位关系的研究”。

O.Kojima: "Inhibition of gastric cancer cell lines by Tamoxifen" J.Kyoto.Pref.Vnic Med. 102. 1421-1427 (1993)

O.Kojima：“他莫昔芬对胃癌细胞系的抑制”J.Kyoto.Pref.Vnic Med。

O.Kojima: "Prognostic factor of gastric carcinoma-Usefulness for prognostic factor and improvement of prognosis in patients with gastric cancer." J.Gastroentero.Surg.2499-2502 (1993)

O.Kojima：“胃癌的预后因素 - 对胃癌患者预后因素和改善预后的有用性”。

O.Kojima: "Inhibition of gastric cancer cell lines by Tamoxifen" J.Kyoto Prefect.Univ.Med.102. 1421-1427

O.Kojima：“他莫昔芬对胃癌细胞系的抑制”J.Kyoto Prefect.Univ.Med.102。